Paradigm4 launches multi-omics app for advanced cross-study analysis

Paradigm4 has launched Reveal: Multi-Omics, an app which allows researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across integrated public reference and proprietary datasets. It is built on top of Paradigm4’s SciDB analytics platform, designed for rapid data slicing that enables scientific data modelling, storage, and population-scale computation.

The app provides biopharmaceutical developers the ability to interrogate omics datasets in a rapid, scalable and cost-effective way, giving them broad insights into disease biology, pathology and the ability to test and support hypotheses from multiple studies. It captures metadata, allowing users to construct data based on experimental details, pipeline analyses, biosample details and annotation fields.

Reveal: Multi-Omics is said to streamline machine-learning across heterogeneous datasets. Data and metadata are curated, quality assured and processed once, allowing users to query multiple data sets repeatedly and reproducibly. Data selection reportedly does not slow down as studies are added.

Zachary Pitluk, VP of Life Sciences and Healthcare at Paradigm4, commented: “Having a clear, multi-dimensional view of ‘omics information allows the testing and confirmation of hypotheses of disease stage and severity, and which pharmaceutical intervention could impact the disease. This really can make a difference in accelerating drug discovery. The Reveal: Multi-Omics app makes it easier for researchers to understand which data is relevant and reliable enough to inform clinical decisions and unlock the ‘ideal state’ of precision medicine.”

Paradigm4’s Reveal apps are a suite of use case-specific applications that power discovery from population-scale to n-of-1.

Image credit: Nordwood Themes

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free